A Comparative Study on the Memory-Enhancing Actions of Oral Renin-Angiotensin System Altering Drugs in Scopolamine-Treated Mice
- PMID: 31106575
- PMCID: PMC10852518
- DOI: 10.1177/1533317519847042
A Comparative Study on the Memory-Enhancing Actions of Oral Renin-Angiotensin System Altering Drugs in Scopolamine-Treated Mice
Abstract
This study was designed to evaluate the spatial working memory (as studied in Y-maze) or short-term and long-term spatial memory (assessed in radial 8 arms-maze task), in a scopolamine-induced memory deficits model in mice, by the oral administration of 2 angiotensin-converting enzyme inhibitors-captopril and ramipril and also the effects of the AT1 receptor antagonist, losartan. The present article was initiated as a reaction to the clinical setting of hypertensive disease, which involves lifelong administration of antihypertensive drugs, dietary or lifestyle constraints, and aging, which all take a toll on the higher functions of the nervous system. Most of the patients with cognitive decline suffer of various metabolic imbalances, hypertension, cardiac and kidney disease, many of them which are treated with oral administration of Renin-angiotensin aldosterone system-altering agents like those presented above. Our results showed a protective effect of captopril, ramipril, and losartan prescopolamine administration on spontaneous alternation in Y-maze task, as compared to scopolamine-alone treated mice, as well as decreased number of working memory errors and reference memory errors in radial-arm maze for both losartan + scopolamine and ramipril + scopolamine groups versus scopolamine alone. This could have a therapeutical relevance, especially since oral administration was preferred in our report, as it is used in the therapeutic procedures in humans, further enhancing the similarities with the clinical conditions.
Keywords: captopril; losartan; memory; oral administration; ramipril; renin–angiotensin system; scopolamine.
Conflict of interest statement
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The authors are stating that there is no conflict of interest to disclose, except for Ciobica Alin who is supported by a Young Teams grant offered by UEFISCDI Romania, no. PN-III-P1-1.1-TE-2016-1210, contract no. 58 from 02/05/2018.
Figures


Similar articles
-
Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm.Neuropeptides. 2001 Feb;35(1):65-9. doi: 10.1054/npep.2000.0845. Neuropeptides. 2001. PMID: 11346312
-
Inhibition of central angiotensin II enhances memory function and reduces oxidative stress status in rat hippocampus.Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:79-88. doi: 10.1016/j.pnpbp.2012.12.009. Epub 2012 Dec 20. Prog Neuropsychopharmacol Biol Psychiatry. 2013. PMID: 23266710
-
No evidence for involvement of angiotensin II in spatial learning in water maze in rats.Behav Brain Res. 1996 Nov;81(1-2):199-205. doi: 10.1016/s0166-4328(96)00062-9. Behav Brain Res. 1996. PMID: 8950017
-
Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.Drugs. 2004;64(22):2537-65. doi: 10.2165/00003495-200464220-00004. Drugs. 2004. PMID: 15516153 Review.
-
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.Expert Opin Ther Targets. 2004 Feb;8(1):7-14. doi: 10.1517/14728222.8.1.7. Expert Opin Ther Targets. 2004. PMID: 14996614 Review.
Cited by
-
Effects of Combined Anti-Hypertensive and Statin Treatment on Memory, Fear Extinction, Adult Neurogenesis, and Angiogenesis in Adult and Middle-Aged Mice.Cells. 2021 Jul 14;10(7):1778. doi: 10.3390/cells10071778. Cells. 2021. PMID: 34359946 Free PMC article.
-
The Impact of Some Modulators of the Renin-Angiotensin System on the Scopolamine-Induced Memory Loss Mice Model.Brain Sci. 2023 Aug 16;13(8):1211. doi: 10.3390/brainsci13081211. Brain Sci. 2023. PMID: 37626567 Free PMC article.
-
Therapeutic Implications of Renin-Angiotensin System Modulators in Alzheimer's Dementia.Pharmaceutics. 2023 Sep 6;15(9):2290. doi: 10.3390/pharmaceutics15092290. Pharmaceutics. 2023. PMID: 37765259 Free PMC article. Review.
-
The COVID-19 pandemic and Alzheimer's disease: mutual risks and mechanisms.Transl Neurodegener. 2022 Sep 11;11(1):40. doi: 10.1186/s40035-022-00316-y. Transl Neurodegener. 2022. PMID: 36089575 Free PMC article. Review.
-
The Brain AT2R-a Potential Target for Therapy in Alzheimer's Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics.Mol Neurobiol. 2020 Aug;57(8):3458-3484. doi: 10.1007/s12035-020-01964-9. Epub 2020 Jun 12. Mol Neurobiol. 2020. PMID: 32533467 Free PMC article. Review.
References
-
- von Bohlen und Halbach O, Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res. 2006;326(2):599–616. - PubMed
-
- Ciobica A, Bild W, Hritcu L, Haulica I. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg. 2009;109(3):171–180. - PubMed
-
- Pederson ES, Harding JW, Wright JW. Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog. Regul Pept. 1998;74(2-3):97–103. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials